Levaquin Claims Should Not Include Intermediate Resistant Strains - Cmte.
A penicillin-resistant community-acquired pneumonia indication for Johnson & Johnson's Levaquin should not mention intermediate resistant strains so as not to encourage overuse, FDA's Anti-Infective Drugs Advisory Committee determined Oct. 20.
You may also be interested in...
FDA is requesting that Ortho-McNeil promote Levaquin responsibly following the Feb. 2 approval of the oral and injectable quinolone for treatment of penicillin-resistant S. pneumoniae in patients with community-acquired pneumonia.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011